Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Gain Therapeutics, Inc. has received a consensus recommendation of "Moderate Buy" from eight brokerages, with a majority issuing buy ratings and an average price target of $7.8571.
• The stock saw a 3.3% increase recently, trading at $1.87, while its 52-week high and low stand at $2.90 and $1.41, respectively.
• The company recently reported quarterly earnings showing a loss of ($0.19) per share, missing analysts' estimates by $0.02.

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $7.8571.

GANX has been the topic of a number of analyst reports. BTIG Research reissued a "buy" rating and issued a $9.00 price target on shares of Gain Therapeutics in a research note on Wednesday. Weiss Ratings reissued a "sell (e+)" rating on shares of Gain Therapeutics in a research note on Wednesday, October 8th. Roth Capital cut their price target on Gain Therapeutics from $7.00 to $6.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. HC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, October 13th. Finally, Maxim Group increased their price target on Gain Therapeutics from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Tuesday, October 7th.

Institutional Trading of Gain Therapeutics

Large investors have recently made changes to their positions in the company. Kovitz Investment Group Partners LLC bought a new stake in shares of Gain Therapeutics in the 1st quarter valued at $91,000. Dauntless Investment Group LLC bought a new stake in shares of Gain Therapeutics in the 1st quarter valued at $240,000. Marshall Wace LLP increased its position in shares of Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company's stock valued at $498,000 after buying an additional 80,407 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company's stock valued at $523,000 after buying an additional 8,251 shares in the last quarter. Institutional investors own 11.97% of the company's stock.

Gain Therapeutics Stock Up 3.3%

NASDAQ:GANX opened at $1.87 on Friday. The stock's fifty day moving average price is $1.80 and its two-hundred day moving average price is $1.78. Gain Therapeutics has a 52-week low of $1.41 and a 52-week high of $2.90. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.79 and a current ratio of 1.79. The company has a market cap of $67.23 million, a price-to-earnings ratio of -2.97 and a beta of 0.11.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). On average, analysts anticipate that Gain Therapeutics will post -1 EPS for the current year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.